Literature DB >> 23179435

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Peter Valent1, Michel Arock, Patrizia Bonadonna, Knut Brockow, Sigurd Broesby-Olsen, Luis Escribano, Karoline V Gleixner, Clive Grattan, Emir Hadzijusufovic, Hans Hägglund, Olivier Hermine, Hans-Peter Horny, Hanneke C Kluin-Nelemans, Marcus Maurer, Marek Niedoszytko, Boguslaw Nedoszytko, Gunnar Nilsson, Hanneke N G Oude-Elberink, Alberto Orfao, Deepti Radia, Andreas Reiter, Frank Siebenhaar, Karl Sotlar, Wolfgang R Sperr, Massimo Triggiani, Jaap J VanDoormaal, Judit Várkonyi, Selim Yavuz, Karin Hartmann.   

Abstract

The European Competence Network on Mastocytosis (ECNM) was initiated in 2002 as a multidisciplinary and multinational cooperative approach to increase awareness and to improve diagnosis and therapy of mastocytosis. The network is composed of local centers, physicians, and scientists who have dedicated their work to patients with mastocytosis. A strategic goal of the ECNM is to provide the best available information about the disease to patients and physicians. During the past 10 years, the ECNM has expanded to various countries and contributed successfully to the development of markers, definitions, and standards in the field of mastocytosis. Members of the ECNM organized Annual Meetings in Europe and two Working Conferences on Mastocytosis in Vienna (in 2005 and 2010), and initiated and supported several preclinical and clinical trials. In all these activities, representatives of the ECNM cooperate closely with their US colleagues, with patient-organizations in Europe and in the USA, and with other scientific networks. The ECNM also launched a mastocytosis registry that has been activated in 2012. Using the central database of this registry, cooperative multicenter studies, which should include sufficient numbers of patients and robust evaluations, will be conducted. These studies will increase our knowledge about optimal management and therapy of patients with mastocytosis in the future.

Entities:  

Mesh:

Year:  2012        PMID: 23179435     DOI: 10.1007/s00508-012-0293-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  44 in total

1.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

Review 2.  Mastocytosis: current concepts in diagnosis and treatment.

Authors:  L Escribano; C Akin; M Castells; A Orfao; D D Metcalfe
Journal:  Ann Hematol       Date:  2002-11-29       Impact factor: 3.673

3.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

Authors:  L Escribano; A Orfao; B Díaz-Agustin; J Villarrubia; C Cerveró; A López; M A Marcos; C Bellas; S Fernández-Cañadas; M Cuevas; A Sánchez; J L Velasco; J L Navarro; J F Miguel
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

Review 4.  Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.

Authors:  P Valent; L Escribano; R M Parwaresch; V Schemmel; L B Schwartz; K Sotlar; W R Sperr; H P Horny
Journal:  Int Arch Allergy Immunol       Date:  1999-09       Impact factor: 2.749

5.  Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

Authors:  R Fritsche-Polanz; J H Jordan; A Feix; W R Sperr; G Sunder-Plassmann; P Valent; M Födinger
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

Review 6.  Gastrointestinal involvement and manifestations in systemic mastocytosis.

Authors:  Harry Sokol; Sophie Georgin-Lavialle; Catherine Grandpeix-Guyodo; Danielle Canioni; Stéphane Barete; Patrice Dubreuil; Olivier Lortholary; Laurent Beaugerie; Olivier Hermine
Journal:  Inflamm Bowel Dis       Date:  2010-07       Impact factor: 5.325

Review 7.  Mast cell proliferative disorders: current view on variants recognized by the World Health Organization.

Authors:  Peter Valent; Cem Akin; Wolfgang R Sperr; Hans-Peter Horny; Dean D Metcalfe
Journal:  Hematol Oncol Clin North Am       Date:  2003-10       Impact factor: 3.722

8.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

Authors:  B J Longley; L Tyrrell; S Z Lu; Y S Ma; K Langley; T G Ding; T Duffy; P Jacobs; L H Tang; I Modlin
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

Review 9.  Mastocytosis: state of the art.

Authors:  Hans-Peter Horny; Karl Sotlar; Peter Valent
Journal:  Pathobiology       Date:  2007       Impact factor: 4.342

10.  Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.

Authors:  H-P Horny; K Sotlar; W R Sperr; P Valent
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

View more
  11 in total

1.  Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.

Authors:  Jakub Trizuljak; Wolfgang R Sperr; Lucie Nekvindová; Hanneke O Elberink; Karoline V Gleixner; Aleksandra Gorska; Magdalena Lange; Karin Hartmann; Anja Illerhaus; Massimiliano Bonifacio; Cecelia Perkins; Chiara Elena; Luca Malcovati; Anna B Fortina; Khalid Shoumariyeh; Mohamad Jawhar; Roberta Zanotti; Patrizia Bonadonna; Francesca Caroppo; Alexander Zink; Massimo Triggiani; Roberta Parente; Nikolas von Bubnoff; Akif S Yavuz; Hans Hägglund; Mattias Mattsson; Jens Panse; Nadja Jäkel; Alex Kilbertus; Olivier Hermine; Michel Arock; David Fuchs; Vito Sabato; Knut Brockow; Agnes Bretterklieber; Marek Niedoszytko; Björn van Anrooij; Andreas Reiter; Jason Gotlib; Hanneke C Kluin-Nelemans; Jiri Mayer; Michael Doubek; Peter Valent
Journal:  Allergy       Date:  2020-03-16       Impact factor: 13.146

Review 2.  The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.

Authors:  Peter Valent; Joanna N G Oude Elberink; Aleksandra Gorska; Magdalena Lange; Roberta Zanotti; Björn van Anrooij; Massimiliano Bonifacio; Patrizia Bonadonna; Karoline V Gleixner; Emir Hadzijusufovic; Cecelia Perkins; Karin Hartmann; Anja Illerhaus; Serena Merante; Chiara Elena; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Rosemarie Greul; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Haifa Kathrin Al-Ali; Marie-Anne Morren; Judit Varkonyi; Alexander Zink; Marek Niedoszytko; Dietger Niederwieser; Luca Malcovati; Andreas Reiter; Vanessa Kennedy; Jason Gotlib; Olivier Lortholary; Olivier Hermine; Michel Arock; Hanneke Kluin-Nelemans; Wolfgang R Sperr
Journal:  J Allergy Clin Immunol Pract       Date:  2018-11-08

3.  Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Authors:  Peter Valent; Elisabeth Aberer; Christine Beham-Schmid; Christina Fellinger; Wolfgang Fuchs; Karoline V Gleixner; Rosemarie Greul; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang R Sperr; Friedrich Wimazal; Stefan Wöhrl; Brigitte Zahel; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2013-05-05

4.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

5.  [Recurrent skin blisters for more than 7 months in a girl aged 15 months].

Authors:  Ke-Yao Li; Jian-Ping Tang; Xiao-Ting Liang; Zhou-Ying Zhao; Shu-Zhen Yue
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-09

6.  Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.

Authors:  Imelda Marton; László Krenács; Enikő Bagdi; Annamária Bakos; Judit Demeter; Zita Borbényi
Journal:  Pathol Oncol Res       Date:  2015-11-06       Impact factor: 3.201

7.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

Review 8.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Authors:  M Arock; K Sotlar; C Akin; S Broesby-Olsen; G Hoermann; L Escribano; T K Kristensen; H C Kluin-Nelemans; O Hermine; P Dubreuil; W R Sperr; K Hartmann; J Gotlib; N C P Cross; T Haferlach; A Garcia-Montero; A Orfao; J Schwaab; M Triggiani; H-P Horny; D D Metcalfe; A Reiter; P Valent
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

9.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290

10.  Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.

Authors:  Peter Valent; Jörg Berger; Sabine Cerny-Reiterer; Barbara Peter; Gregor Eisenwort; Gregor Hoermann; Leonhard Müllauer; Christine Mannhalter; Michael Steurer; Peter Bettelheim; Hans-Peter Horny; Michel Arock
Journal:  Ann Hematol       Date:  2014-09-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.